Copyright
©The Author(s) 2016.
World J Diabetes. Dec 15, 2016; 7(20): 572-598
Published online Dec 15, 2016. doi: 10.4239/wjd.v7.i20.572
Published online Dec 15, 2016. doi: 10.4239/wjd.v7.i20.572
Figure 14 Liraglutide 3 mg shows greater, dose dependent, reductions in body weight compared to placebo and orlistat with maximal effect between 0-20 wk of treatment.
Red line dotted trace shows patters of weight loss from baseline in those subjects treated with 3 mg liraglutide. Greatest rate of weight loss was observed between 0-20 wk, reducing from 20-36 with a tendency toward weight gain from 36 wk and beyond.
- Citation: Anandhakrishnan A, Korbonits M. Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity. World J Diabetes 2016; 7(20): 572-598
- URL: https://www.wjgnet.com/1948-9358/full/v7/i20/572.htm
- DOI: https://dx.doi.org/10.4239/wjd.v7.i20.572